Updated August 6, 2026: Clarified that the ban targets hemp inflorescences and flower-derived products (seed- and stalk-derived CBD remains outside its scope), noted the June 2025 conversion into Law 80/2025, and added the November 2025 CJEU referral and the Council of State's December 2025 suspension of the oral-CBD medicines decree.

Understanding Italy CBD Ban 2025: Overview of Decree-Law 48/2025

Italy’s adoption of Decree-Law 48/2025 in April 2025 sent seismic waves through the European hemp and CBD sector. The new measure, passed under the guise of public order and security and converted with amendments into Law 80/2025 in June 2025, treats hemp inflorescences and flower-derived products—including Cannabidiol (CBD) extracted from hemp flowers—as narcotics. This decision has grave implications for hemp growers, retailers, e-commerce operators, and wellness brands shipping into or operating in Italy.

This article provides an up-to-date breakdown of the ban’s scope, enforcement actions, compliance challenges, and looming legal uncertainties.

Scope of the Italy CBD Ban 2025

Under Decree-Law 48/2025 and related administrative court rulings (source, source), hemp inflorescences and flower-derived CBD products—whether for oral consumption, vaping, cosmetic use, or floral display—are treated as narcotics. CBD derived exclusively from the seeds, leaves, and stalks of certified industrial hemp remains outside the flower ban, though in practice it faces heavy documentation demands and seizure risk. Key features include:

• Prohibition on Production and Retail Sales: Industrial hemp flowers and flower-derived CBD products, including oils and vapes, are banned from all forms of retail sale, impacting both brick-and-mortar and online stores.
• E-Commerce and Import Restrictions: The new classification has triggered heightened customs scrutiny and product seizures at Italian borders, hitting DTC shipping and B2B supply chains.
• Impact on Cosmetics: CBD cosmetics, previously allowed under EU Cosmetics Regulations, must now pass through Italy’s narcotics control regime and risk seizure when sourced from inflorescences.

The only permitted products remain those specifically authorized as medicinal cannabis under prescription, with strict controls and traceability maintained by national health authorities (details), plus hemp-seed foods and seed/stalk-derived CBD products that fall outside the inflorescence ban.

Enforcement: Seizures, Raids, and Immediate Impact

Since passage of Decree-Law 48/2025, Italian law enforcement and health authorities have conducted an aggressive crackdown, including:

• Inspections of retail outlets, seizing hemp flower stock and CBD edibles.
• Customs checks and seizures targeting e-commerce parcels, DTC shipments, and wholesale imports.
• Legal notices sent to operators warning against continued trade in banned products.

These actions have created an atmosphere of uncertainty and risk for all supply chain actors. There have been reports of on-the-spot closures for non-compliant retailers and confiscation of goods in transit (source).

Immediate Compliance Considerations for Businesses

Operators shipping or selling into the Italian market should enact a precautionary stance:

1. Reassess Product Lines and Distribution

• Treat Italy as an exclusion market for most CBD SKUs until regulatory clarity improves.
• Employ geoblocking measures for Italian IP addresses on DTC (direct-to-consumer) websites.

2. Review Customs and Ingredient Declarations

• Scrutinize HS codes, ingredient lists, and product claims for all Italy-bound shipments.
• Be prepared for documentation demands from customs authorities or law enforcement.

3. Distributor and Channel Indemnities

• Adapt commercial agreements to reflect increased regulatory risk and potential seizure liability.

4. Cosmetics Require Separate Due Diligence

• Cosmetic SKUs containing CBD now fall under both narcotics law and EU Cosmetics Regulation. Cross-jurisdictional dossiers should be reassessed, and companies should expect regulatory pushback, even for products lawfully marketed elsewhere in the EU (background).

5. Monitor Ongoing Litigation and EU Law Developments

• Track court challenges, especially those invoking EU free movement of goods and the 2020 Kanavape case precedent.

Regulatory Uncertainty: Legal Challenges and EU Friction

Italy’s emergency CBD ban stands at odds with recent European Court of Justice (ECJ) jurisprudence, particularly the 2020 Kanavape decision, which emphasizes that non-psychoactive hemp and CBD are not narcotics under international conventions if lawfully produced in an EU member state. Consequently:

• Court Challenges were lodged by industry groups and importers by early summer 2025. Several operators have argued that the Italian law violates foundational EU principles regarding the free movement of goods.
• In November 2025, Italy’s Council of State referred the flower ban to the Court of Justice of the EU, asking whether it violates EU rules on agricultural products and the free movement of goods; that referral remained pending as of August 2026.
• In December 2025, the Council of State suspended the separate decree classifying oral CBD compositions as prescription-only narcotic medicines, pending a final ruling.
• The Court of Brindisi has separately referred the ban's Article 18 to Italy’s Constitutional Court on proportionality grounds.
• Despite these challenges, the national flower ban remains officially in force (latest summary), and outcomes and timelines remain uncertain.

Consumer Implications: What’s Legal and What Isn’t

As of August 2026, Italian consumers should assume:

• CBD Oils, Edibles, Vape Products: Flower-derived products are not legally available for retail or personal import. Products made exclusively from hemp seeds or stalks remain lawful but face scrutiny.
• Hemp Flower and Derivatives (Non-Medicinal): Banned from sale, possession subject to legal risk.
• Prescribed Medical Cannabis: Still permitted via tightly controlled pharmaceutical channels.
• Cosmetic Products with CBD: At high risk of seizure and regulatory rejection, despite ongoing legal appeals.

Consumers traveling into Italy or ordering from abroad should exercise extreme caution, as seizures and penalties can apply even for possession of small quantities acquired legally elsewhere.

Cross-Border Trade: Practical Impacts and Recommendations

International brands and EU operators face significant compliance exposure when trading with Italy:

• Customs enforcement: Expect robust scrutiny of all imports labeled as containing hemp or CBD. Even compliant cosmetics or supplements with trace CBD are likely to be held or destroyed.
• Country-specific lineoffs: Consider launching Italy-excluded assortments until further notice.
• Contractual indemnities: Ensure clear assignment of seizure risk and legal liability with all distributors and cross-border partners operant in Italy.
• Monitor regulatory updates: Rapid legal developments require continual review of operational risk and compliance strategies.

Outlook: Legislative, Judicial, and Regulatory Pathways

Over the coming months, stakeholders should monitor these key streams:

• Court rulings and preliminary injunctions that may limit or clarify the scope of Decree-Law 48/2025, above all the pending CJEU referral and the Constitutional Court question.
• Potential EU infringement procedures if the Commission determines the law breaches single market rules.
• Lobbying and industry advocacy, particularly by hemp and wellness trade groups, to secure carve-outs or a reversal of the emergency ban.

With respect to enforcement, the landscape remains fluid and high-risk. As of August 2026, there is no formal timeline for repeal or amendment, the default position is a broad-based prohibition on flower-derived products, and the pending CJEU referral is the most likely inflection point.

Key Takeaways for Cannabis Businesses and Consumers

• The Italy CBD ban 2025 under Decree-Law 48/2025 (now Law 80/2025) is among Europe’s strictest and carries substantial legal risk for non-compliance.
• All supply chain participants should halt Italy-focused product flows involving flower-derived CBD and hemp inflorescences until further legal clarity is available.
• Robust country-specific compliance checks, distributor indemnities, and active monitoring of legal appeals are essential.
• The compliance landscape is likely to shift rapidly as EU and Italian courts grapple with the legality of the new regime.

For ongoing regulatory tracking, compliance strategy, and up-to-date intelligence on the Italy CBD ban 2025 and other global cannabis rules, trust CannabisRegulations.ai as your source for clarity in an evolving market.